Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
The Champions League league phase is coming to an end. In a breath-stopping final matchday, with all 18 games kicking off simultaneously, almost everything is still up for grabs. The only certainties ...